Epilepsy Drugs Market - Growth, Trends, and Forecast (2020 - 2025)
|発行||Mordor Intelligence LLP||商品コード||921243|
|出版日||ページ情報||英文 114 Pages
|てんかん治療薬の世界市場：成長、動向、および予測 Epilepsy Drugs Market - Growth, Trends, and Forecast (2020 - 2025)|
|出版日: 2020年01月01日||ページ情報: 英文 114 Pages||
The major factors for the growth of the epilepsy drugs market include the rise in the new drug approvals over the past few years, increasing cases of epilepsy, and raising awareness about the condition across the globe.
Epilepsy is a central nervous system (CNS) disorder in which brain activity becomes abnormal, resulting in seizures or periods of unusual behavior, and sensations. It can occur due to a genetic disorder or an acquired brain injury. According to the data published by the Epilepsy Foundation, in the United States, in 2015 around 1.2% of the population or 3 million adults had active epilepsy which was an increase from 2.3 million adults with active epilepsy in 2010. Furthermore, as per the data published by the World Health Organization (WHO) epilepsy accounts for a significant proportion of the population affecting around 50 million people worldwide. In addition to the rising cases of epilepsy, there is a rising effort taken to increase awareness about the condition. One of the organization's Epilepsy Foundation is promoting public awareness and education by undertaking research and delivering specialist medical care and support services to the people affected by epilepsy.
As per the scope of this report, epilepsy drugs do not cure epilepsy but helps to control seizures. The drugs are classified into three major segments first generation, second generation, and third generation. The market is segmented by drugs, distribution channels, and geography.
Second Generation is the Segment by Drugs expected to Hold Largest Market Share over the Forecast Period
The second-generation drugs are expected to hold the largest market share owing to the several significant advantages such as reduced drug-drug interactions, less life-threatening adverse events and less negative impact on cognitive functions. Furthermore, the rising cases of epilepsy will boost the demand for drugs in the market. Also, recently in May 2018 one of the market player UCB announced that the United States Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for its newest anti-epileptic drug (AED) BRIVIACT (brivaracetam) CV oral formulations indicated as monotherapy and adjunctive therapy in the treatment of partial-onset (focal) seizures in patients aged four years and older. Thus, owing to the new product launch and acceptance of second-generation epilepsy drugs the market is expected to witness high growth over the forecast period.
North America is Expected to Hold Largest Market Share over the Forecast Period
The United States is expected to be the largest epilepsy drug market owing to the presence of better healthcare infrastructure and rising cases of epilepsy. As per the new Morbidity and Mortality Weekly Report from the CDC, around 3.4 million people in the United States live with seizures, including 470,000 children. While, despite all available treatments, 4 out of 10 people with epilepsy continue to experience uncontrolled seizures while many more experience less than optimal seizure control. Thus, there is a rising demand for effective treatment in the region which is expected to boost the growth of the market. Furthermore, there are various organizations making awareness about epilepsy in the United States. For instance, the Epilepsy Foundation is a non-profit organization in the United States, raises public awareness to increase understanding of seizures and dispel myths. Thus, owing to the all above-mentioned factors the market is expected to witness high growth.
The market studied is a consolidated market owing to the presence of a few major market players. Some of the market players are Abbott Laboratories, GlaxoSmithKline PLC, Johnson & Johnson Health Care Systems Inc., Novartis AG, Pfizer, Inc., Sanofi SA, Sunovion Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, and UCB S.A.,